▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2810 by analyst upside · 2026-06-27
VRTX
Vertex Pharmaceuticals Incorporated
Healthcare · Market Cap $125B · P/E 28.5x
ANALYST PRICE TARGET
+11.7%
implied upside to consensus target
Current Price $491.34
Consensus Target $548.69
Bull Target $641.0
Bear Target $330.0
Analysts Covering 29
ANALYST CONSENSUS — BUY
Strong Buy
4
Buy
19
Hold
4
Sell
2
52-Week Low $362.5
52-Week High $507.92
YTD Return +8.7%
FUNDAMENTALS
Market Cap $125B
P/E Ratio (TTM) 28.5x
Forward P/E 22.9x
EPS (TTM) $17.25
PEG Ratio 1.79
Dividend Yield N/A
Revenue (TTM) $12.2B
Profit Margin 35.5%
52-WEEK RANGE
52-Week Low $362.5
52-Week High $507.92
Current Price $491.34
Bear Target $330.0
Bull Target $641.0
● Now $491.34 ● Target $548.69
TRADING DATA
Avg Volume 1.3M
YTD Return +8.7%
Analyst Count 29
Consensus Buy
Upside to Target +11.7%
Last Updated 2026-06-27

ANALYST SUMMARY

Vertex Pharmaceuticals Incorporated (VRTX) is currently trading at $491.34 with a Wall Street consensus price target of $548.69, implying potential upside of 11.7% over the next 12 months. 29 analysts currently cover VRTX, with a consensus rating of Buy — 79% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $641.0, while the most cautious has a target of $330.0.

VRTX operates in the Healthcare sector with a market capitalisation of $125B. The stock is up 8.7% year-to-date and is currently trading near the upper end of its 52-week range of $362.5 – $507.92.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

SYK +16.3%
Stryker Corporation
$128B · P/E 36.6x · Buy
DHR +23.5%
Danaher Corporation
$139B · P/E 38.0x · Buy
CVS +1.0%
CVS Health Corporation
$133B · P/E 46.0x · Buy
MDT +21.0%
Medtronic plc
$104B · P/E 21.7x · Buy
GILD +23.2%
Gilead Sciences, Inc.
$159B · P/E 17.4x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for VRTX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Barclays — Reiterated
Overweight → Overweight 2026-05-06 Building track record
Canaccord Genuity — Reiterated
Hold → Hold 2026-05-05 Building track record
Morgan Stanley — Reiterated
Overweight → Overweight 2026-05-05 Building track record
Bernstein — Reiterated
Outperform → Outperform 2026-05-05 Building track record
RBC Capital — Reiterated
Outperform → Outperform 2026-05-05 Building track record
Canaccord Genuity — Reiterated
Hold → Hold 2026-04-30 Building track record
Morgan Stanley — Reiterated
Overweight → Overweight 2026-04-10 Building track record
Maxim Group ↑ Upgrade
Hold → Buy 2026-03-18 28% win rate (40 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
—
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →